AJINOMOTO CO., INC.

PCI Pharma Services to Acquire Ajinomoto Althea, Expanding US Fill-Finish Capabilities

25 days ago

• PCI Pharma Services is acquiring Ajinomoto Althea, a US-based sterile fill-finish CDMO, with the transaction expected to close in May 2025. • The acquisition provides PCI with its first North American manufacturing location for prefilled syringes and cartridges, plus high potent manufacturing capabilities for antibody-drug conjugates. • Althea's San Diego facilities will create a major manufacturing hub in Southern California's biopharma corridor, complementing PCI's existing clinical trial services in the region.

Clinical Trial Evaluates Safety and Efficacy of L-Arginine Supplementation in ALS Patients

5 months ago

A recent clinical trial investigated the safety and potential benefits of oral L-arginine hydrochloride supplementation in patients with Amyotrophic Lateral Sclerosis (ALS). The study, conducted over 90 days, found that L-arginine was well tolerated with no serious adverse events or deaths related to the intervention. It also suggested a correlation between L-arginine levels and the maintenance of body weight, an important indicator of nutritional status in ALS patients.